China Diabetes Care Devices Market Overview, 2031

Key Insights

• According to the research report, "China Diabetes Care Devices Market Outlook, 2031," published by Bonafide Research, the China Diabetes Care Devices Market is expected to reach a market size of more than 10.25 Billion by 2031.
• The Chinese diabetes care devices market is undergoing a rapid transition from traditional Self-Monitoring Blood Glucose (SMBG) systems to locally manufactured Continuous Glucose Monitoring (CGM) systems. While multinational companies historically dominated high-end hospitals, domestic medical device manufacturers such as Sinocare, MicroTech Medical, Sano Medical, and Meiqi Medical have achieved significant regulatory breakthroughs with National Medical Products Administration (NMPA) clearances for factory-calibrated, calibration-free CGMs.
• Beyond continuous monitoring, China is seeing accelerated commercialization of closed-loop automated insulin delivery (AID) algorithms and tubeless smart patch pumps. Local medtech innovators have secured NMPA approvals for domestic patch pump platforms and interoperable AID algorithms that dynamically pair with real-time CGMs. These platforms evaluate glycemic trends continuously and adjust insulin infusion automatically, protecting Type 1 and severe insulin-dependent Type 2 diabetes patients against dangerous hypoglycemic events.
• Crucially, roughly 49.7% of the adult cohort representing over 73.5 million individuals remains formally undiagnosed, alongside more than 117.2 million adults presenting with Impaired Fasting Glucose (IFG) or prediabetes. Type 1 diabetes affects over 598,000 individuals across all age brackets in China, including more than 116,000 children and adolescents. From an economic perspective, total direct annual health expenditures attributed to diabetes management in China exceed $168.8 billion USD. This massive patient base drives urgent national demand for cost-effective self-monitoring equipment, disposable insulin delivery pens, and digital health interventions to reduce severe vascular complications.

Market Outlook

• The market outlook for diabetes care devices in China is increasingly driven by direct-to-consumer (DTC) e-commerce channels, retail pharmacy expansion, and cloud-connected digital platforms. Major e-commerce ecosystems (such as JD Health, Tmall Health, and Pinduoduo) serve as primary sales channels for over-the-counter continuous biosensors, SMBG test strips, and smart insulin pen accessories.
• Medical device clearances, manufacturing compliance, and post-market safety are governed nationally by the National Medical Products Administration (NMPA), while clinical guidelines and research standards are established by the Chinese Diabetes Society (CDS) and the Chinese Medical Association (CMA). Prominent domestic and multinational companies driving the commercial marketplace in China include Sinocare Inc., MicroTech Medical, Sano Medical, Abbott Laboratories China, Dexcom, Medtronic China, Roche Diabetes Care China, and Ypsomed China.

Market Dynamics

Driver: Critical disease prevalence and government chronic disease mandates
The primary growth driver for China’s diabetes care devices market is the country’s massive disease burden combined with targeted national health initiatives. China is home to the world’s largest diabetic population, with over 147 million adults living with the condition and tens of millions remaining undiagnosed. As disposable incomes rise and urban middle-class populations gain greater purchasing power, there is a marked willingness to spend out-of-pocket on advanced medical hardware such as Continuous Glucose Monitoring (CGM) systems, smart insulin pens, and continuous insulin pumps.
Challenge: Price erosion and public reimbursement bottlenecks
Despite immense patient volume, medical device manufacturers operating in China face severe profit margin compression due to national and provincial Volume-Based Procurement (VBP) policies. Designed by the National Healthcare Security Administration (NHSA) to reduce healthcare costs, VBP tenders group medical consumables and diagnostic equipment into centralized bidding pools. To secure guaranteed sales volumes in public Tier-3 and Tier-2 state hospitals, manufacturers both domestic and multinational are forced to offer drastic price reductions, often exceeding 50% to 70% off retail prices.
Trend: Deep e-commerce penetration (DTC Channels) and integration with mobile mini-programs
A defining trend reshaping China’s diabetes market is the migration of device sales toward direct-to-consumer (DTC) pharmacy e-commerce platforms paired with WeChat mini-program ecosystems. Given that public hospital VBP policies compress margins and public reimbursement for outpatient devices remains sparse, manufacturers are increasingly bypassing traditional hospital procurement routes. Platforms such as JD Health, Tmall Health, and Pinduoduo have become the dominant sales channels for continuous glucose sensors, SMBG test strips, and smart pen accessories.

Segment Analysis

China Diabetes Care Devices By Product Type
• The Chinese blood glucose monitoring systems market is shaped by the coexistence of affordable traditional meters, domestically manufactured testing supplies, and increasingly sophisticated continuous glucose monitoring technologies. Conventional meters and test strips remain practical for routine self-testing, particularly where affordability and easy access to consumables are priorities. Meanwhile, continuous glucose monitoring systems are gaining importance by helping users identify glucose fluctuations and share readings with healthcare professionals through connected applications. A distinctive market feature is the role of domestic manufacturers in supplying cost-conscious products alongside international brands offering advanced sensors and digital connectivity.
• The Chinese insulin delivery devices market encompasses insulin syringes, reusable and disposable pens, insulin pumps, and increasingly connected systems that combine glucose monitoring with automated insulin adjustment. Pens remain a practical choice for many patients because of their portability and familiarity, while pumps and automated delivery technologies offer greater dosing flexibility for people requiring intensive insulin therapy. A distinctive feature of China is the interaction between domestic medical technology innovation, NMPA registration, hospital purchasing procedures, and patient affordability. Local manufacturers have opportunities to compete through cost-conscious designs, connected pens, patch pumps, and integrated systems that reduce the complexity of daily treatment.



China Diabetes Care Devices By Disease Type
• The Chinese type 1 diabetes care devices segment is characterized by the need for continuous glucose monitoring, precise insulin administration, and sustained clinical support. Continuous glucose monitors, insulin pumps, and automated insulin delivery systems help users manage glucose fluctuations associated with meals, physical activity, sleep, and illness. Specialist endocrinology departments in major hospitals play an important role in evaluating advanced technologies, training patients, and supporting treatment adjustments. A distinctive market consideration is the contrast between the growing availability of domestically developed devices and differences in access to specialist services across urban and less-developed regions.
• The Chinese type 2 diabetes care devices segment serves patients with varied treatment needs, from individuals managing glucose through lifestyle changes and oral medications to those requiring insulin therapy. Traditional blood glucose meters remain important for routine monitoring, while continuous glucose monitoring systems can help selected patients understand glucose changes associated with meals, exercise, and medication. A defining market characteristic is the need to balance affordability and broad accessibility with the increasing demand for connected monitoring technologies.

China Diabetes Care Devices By End User
• The Chinese home and self-care segment is shaped by increasing patient participation in diabetes management, widespread use of personal glucose meters, and growing interest in connected monitoring devices. Blood glucose meters, continuous glucose monitors, insulin pens, and wearable pumps allow patients to manage treatment outside healthcare facilities, while mobile applications can support glucose tracking and information sharing with caregivers or clinicians. Online pharmacies and e-commerce platforms provide additional channels for obtaining devices and recurring consumables, although medical device registration, product authenticity, and after-sales service remain important considerations.
• The Chinese hospital segment is an important setting for glucose assessment, inpatient diabetes management, insulin administration, and the introduction of advanced monitoring technologies. Point-of-care glucose meters support timely treatment decisions, while continuous glucose monitors and insulin delivery systems may be used according to clinical needs and institutional protocols. Large hospitals and specialist endocrinology departments are particularly important for evaluating complex devices, educating patients, and coordinating treatment for people requiring intensive insulin management.
• The Chinese diagnostic centers segment supports diabetes screening, glucose assessment, and the clinical investigation of patients who require further evaluation. Laboratory glucose testing and point-of-care measurements remain important for diagnostic workflows, while professional continuous glucose monitoring can provide additional information about daily glucose patterns when clinically appropriate. These facilities prioritize reliable equipment, standardized testing procedures, efficient reporting, and timely communication with referring clinicians. Digital integration can help transfer findings between laboratories, hospital information systems, and specialist diabetes services, supporting more coordinated follow-up.
The Chinese ambulatory surgical centers segment has specialized diabetes device requirements because glucose management must be coordinated with preoperative fasting, anesthesia, outpatient procedures, and postoperative recovery. Point-of-care glucose meters help clinical teams assess glucose levels around surgery, while insulin administration must follow individual treatment plans and established perioperative protocols. These facilities prioritize dependable measurements, rapid workflows, clear documentation, and staff familiarity with diabetes-related risks. For patients using insulin pumps or continuous glucose monitors, clinical teams need procedures for determining whether devices can safely remain in use during a procedure or whether alternative monitoring and insulin delivery arrangements are necessary.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Diabetes Care Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Blood Glucose Monitoring Systems
• Insulin Delivery Devices

By Disease Type
• Type 1 Diabetes
• Type 2 Diabetes

By End User
• Home/Self-Care
• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers